心血管巨头挥师医美！乐普医疗“童颜针”获批

Group 1 - The core viewpoint is that Lepu Medical has officially entered the aesthetic medicine market with the approval of its self-developed polylactic acid facial filler, marking a significant strategic move into consumer healthcare [1][2] - The newly approved product is expected to fill a gap in the dermatology field and is seen as a milestone for the company, with anticipated positive contributions to its performance [2][3] - The company is facing declining growth in its main business, with a reported revenue of 1.736 billion yuan in Q1 2024, down 9.67% year-on-year, and a net profit of 379 million yuan, down 21.44% year-on-year, indicating a need for new growth avenues [3] Group 2 - Lepu Medical's ambitions in the aesthetic field extend beyond the facial filler, as its subsidiary has submitted an application for a botulinum toxin product, targeting a domestic market worth over 6 billion yuan [4] - The aesthetic medicine market is becoming increasingly competitive, with several existing products already in the market, including those from competitors like Aimeike and Sihuan Pharmaceutical [2][5] - The entry of major pharmaceutical companies into the aesthetic market indicates a shift towards a more robust and competitive landscape, where Lepu Medical's experience in medical device development may provide a commercial advantage [5]